Thomas Kaindl
YOU?
Author Swipe
View article: Lisavanbulin (BAL101553), a novel microtubule inhibitor plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
Lisavanbulin (BAL101553), a novel microtubule inhibitor plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma Open
Background Lisavanbulin (BAL101553) is a small, lipophilic, oral microtubule destabilizer with promising antitumoral activity observed in preclinical glioblastoma (GBM) models. Methods This multicenter Phase 1 study sought to determine the…
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours Open
Background BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. Methods This two-part, open-…
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors Open
Summary Purpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity. We investigated an alternativ…
Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases Open
Plasma concentrations of isavuconazole were reasonably consistent between subjects and sampling times, and were not associated with differences in outcomes.
View article: Cell-cell contact dictates life or death decisions following CD95 activation in cancer
Cell-cell contact dictates life or death decisions following CD95 activation in cancer Open
Cancer cells react to CD95 activation with either apoptotic or tumorigenic responses. Yet, the determinants of these two antithetic reactions are fundamentally not understood. Here, we show that pre-confined CD95L molecules activate apopto…